

## **Oregon Medical Group Infusion Center**

1007 Harlow Road, Springfield, Oregon 97477 Phone: 541-741-0387 Fax: 541-242-4634

## Rituximab (Ruxience, Truxima, Rituxan) Orders

		DOB:	
cation:		ICD-10 Code:	
Hei	ght:	BSA:	
xima, followed by Rituxa vr (Ruxience) bs (Truxima)	an		
_	-	Chloride for a total volum	e of 500 mL. Follow
•		for a total volume of 500	mL per pharmaceutical
X 375mg/m²=	mg (r	ound to nearest 100mg) =	mg
protocol for drip rate gu of Rituximab (select all the losing: Every 2 weeks attendance Dosing: Repeat 1	idelines. hat apply): x 2 doses (Day rituximab on d	1 and Day 15) ay 1 and day 15 every	
			if available.
Initial, Q 15-30 minutes	, PRN		
Protocol for Infusions R  nister the following routi  Acetaminophen (Tyle  Antihistamine (Select  Diphenhydra  Diphenhydra  Loratadine (C  Methylprednisolone (	equiring Pre-Mine pre-medical enol) 650 mg Pot one) amine (Benadry Claritin) 10 mg (Solu-Medrol) (Solu-Medrol)	Medication  Itions prior to each infusion  VI) 25 mg PO VI) 25 mg IV infusion over < 1 PO 40 mg IV infusion over < 10 m 100mg IV infusion over < 10 m	o mins nin, not to exceed 50 mg/min
	Hei  oduct(s) willing to prescr xima, followed by Rituxa vr (Ruxience) bbs (Truxima) ituxan). If only selecting  mab 1000mg mixed with protocol for drip rate gu  mab mixed with 0.9% Soo p rate guidelines as calcu X 375mg/m²=  mabmg mixed protocol for drip rate gu  of Rituximab (select all the language of Rituximab (select all the language) for Ritux	Height:	wy (Ruxience) abs (Truxima) ituxan). If only selecting Rituxan, please indicate reason for med ituxan). If only selecting Rituxan, please indicate reason for med mab 1000mg mixed with 0.9% Sodium Chloride for a total volume protocol for drip rate guidelines. mab mixed with 0.9% Sodium Chloride for a total volume of 500 prate guidelines as calculated below: X 375mg/m²=mg (round to nearest 100mg) = mabmg mixed with 0.9% Sodium Chloride for a total v protocol for drip rate guidelines. of Rituximab (select all that apply): l Dosing: Every 2 weeks x 2 doses (Day 1 and Day 15) tenance Dosing: Repeat rituximab on day 1 and day 15 every  Every 2 weeks x 2 doses (Day 1 and Day 15) tenance Dosing: Repeat rituximab on day 1 and day 15 every  Every 2 weeks x 2 doses (Day 1 and Day 15) tenance Dosing: Repeat rituximab on day 1 and day 15 every  Every 2 weeks x 2 doses (Day 1 and Day 15) tenance Dosing: Repeat rituximab on day 1 and day 15 every  Every 2 weeks x 2 doses (Day 1 and Day 15) tenance Dosing: Repeat rituximab on day 1 and day 15 every  Every 2 weeks x 2 doses (Day 1 and Day 15) tenance Dosing: Repeat rituximab on day 1 and day 15 every  Every 2 weeks x 2 doses (Day 1 and Day 15) tenance Dosing: Repeat rituximab on day 1 and day 15 every  Every 2 weeks x 2 doses (Day 1 and Day 15) tenance Dosing: Repeat rituximab on day 1 and day 15 every  Every 2 weeks x 2 doses (Day 1 and Day 15) tenance Dosing: Repeat rituximab on day 1 and Day 15) tenance Dosing: Repeat rituximab on day 1 and Day 15) tenance Dosing: Repeat rituximab on day 1 and Day 15 tenance Dosing: Repeat rituximab on day 1 and Day 15 tenance Dosing: Repeat rituximab on day 1 and Day 15 tenance Dosing: Repeat rituximab on day 1 and Day 15 tenance Dosing: Repeat rituximab on day 1 and Day 15 tenance Dosing: Repeat rituximab on day 1 and Day 15 tenance Dosing: Repeat rituximab on day 1 and Day 15 tenance Dosing: Repeat rituximab on day 1 and Day 15 tenance Dosing: Repeat rituximab on



## **Oregon Medical Group Infusion Center**

1007 Harlow Road, Springfield, Oregon 97477 Phone: 541-741-0387 Fax: 541-242-4634

5. First infusion of each cycle starts @ 50mg/hr. Increase rate by 50mg/hr if no hypersensitivity reaction observed, every 30 minutes. Maximum infusion rate is 400mg/hr. If no hypersensitivity reaction during first infusion, subsequent infusions in same cycle may be started @ 100mg/hr. Increase rate 100mg/hr every 30 minutes to a maximum infusion rate of 400mg/hr.

6. For infusion	reaction (Must select one to be considered a	<u>compiete oraer</u> )
☐ Acute Infu	sion Reaction Protocol	
□ Other		
initiation of treat providers). If a p	B surface antigen and core antibody total) screeniment and the patient should not be infected. Pleas atient is high risk for TB exposure, a Tuberculin te initiation of treatment (PPD or QuantiFERON Go providers).	se send results with order (non-OMG st must have been placed and read as
Provider Signat	ure:	Date:
C	(NO PROVIDER STAMPS)	(Orders expire after 365 days)
Provider's Prin	ted Name:	Time:
Patient Name:		DOB: